



Federaal Kenniscentrum voor de Gezondheidszorg  
Centre Fédéral d'Expertise des Soins de Santé  
Belgian Health Care Knowledge Centre

# Introduction to the KCE methods guides

Mr Patrice X. Chalon, MSc, Knowledge manager



# Plan





# BACKGROUND



# KCE – history



- **Federal agency (semi-governmental)**
- **Established in Dec. 2002**
- **Started with 10 people**



- **KCE = Federaal **K**enniscentrum voor de Gezondheidszorg - **C**entre fédéral d'**E**xpertise des soins de santé**

# KCE - today



63

active members since 2016



# KCE - outputs

**KCE reports:  
287 published since 2004  
(5 “Methods”)**

**“KCE has read for you”:  
17 published since 2012**

KCE REPORT 187C



## THE USE OF QUALITATIVE RESEARCH METHODS IN KCE STUDIES



2012

www.kce.fgov.be

be


## FULLY BIORESORBABLE SCAFFOLDS FOR CORONARY ARTERY DISEASE



- This KCE has read for you was prepared by Lorena San Miguel, Nadia Benahmed
- Published on 18 February 2016

### KEY MESSAGES

- Percutaneous coronary intervention (PCI) with stents is the most common procedure to restore blood flow in the management of obstructive coronary artery disease. Recently, Bioresorbable Vascular Scaffolds/stents, made from a naturally resorbable material, have been presented as an alternative to other PCI techniques.
- According to a systematic review published by Ludwig Boltzmann Institute\* for Health Technology Assessment in March 2015<sup>1</sup>, the available evidence is currently insufficient to show that Bioresorbable Vascular Scaffolds/stents are at least as effective and safer than drug eluting stents in coronary artery disease. The authors recommend to re-assess the evidence in 2018, when results from some of the ongoing trials are expected to become available.



### SUMMARY OF THE PUBLICATION

- Zechmeister-Koss I, Rothschedl E. Fully bioresorbable scaffolds for coronary artery disease. Decision Support Document Nr. 81; 2015. Vienna: Ludwig Boltzmann Institute for Health Technology Assessment.

[CLICK TO READ MORE](#)



# MILESTONES



2003





2003



The University of Birmingham



Procesdoc 4 Search for Evidence

**1 Inhoud**

- Inhoud
- Omschrijving Proce...
- Randvoorwaarden v...
- Krachtlijnen voor h...
- Ingassing /afstemm...
- Flow
- Beschrijving Flow...
- Informatie voor per...
- Consolidatie behoef...
- Openstaande Vrage...

**2 Omschrijving Proce...**

De doelstelling van dit of gedeeltelijk afdoend De zoektocht naar de methodologieën. Afhu doeltreffendheid, ecom informatie te verzame instellingen. De eerste

**3 Randvoorwaarden**

Het opsporen van goed

- De comj door de

Procesdoc 05 Onderzoek van de gegevens

**Inhoud**

- Inhoud
- Omschrijving Proce...
- Randvoorwaarden voor l...
- Krachtlijnen voor het p...
- Ingassing /afstemming...
- Flow
- Beschrijving Flow
- Oplijsting proces, deel...
- Informatie voor persone...
- Consolidatie behoeften...
- Openstaande Vragen

**2 Omschrijving Proce...**

In dit proces wordt vet noodzakelijke data te v studieproject.

De omschrijving in deze data progressief worden

**Randvoorwaarden voor**

*M.b.t. onderzoek op pe*

- Zie ook PR12 voi
- Elke project van door het Sectori houdende socia Gezondheidszor
- Onder *gkappe* semestrieel inge ingezameld bij d...

**3 Randvoorwaarden voo**

Het beoordelen van de kw het uitvoeren van critical bijscholing en door de exp

Procesdoc 6 Kritische verwerking van informatie en analyse van gegevens

**1 Inhoud**

- Inhoud
- Omschrijving Proce...
- Randvoorwaarden voor l...
- Krachtlijnen voor het p...
- Ingassing /afstemming...
- Flow
- Beschrijving Flow
- Oplijsting proces, deel...
- Informatie voor persone...
- Consolidatie behoeften...
- Openstaande Vragen

**1 Omschrijving var**

Dit proces vormt het geaccrediteerde regels Het rapport omvat een

Teneinde het gewenste van de projecten de mb

**2 Beschrijving du pr**

La définition de la not qualité, de l'exactitude terme de validation. A l qu'un processus déteri préalable" (Huber, 199

**2 Randvoorwaarde**

Qua inhoud dient de wetenschappelijke publ installaties

Procesdoc 7 Synthese

**Inhoud**

- Omschrijving van h...
- Randvoorwaarden ...
- Krachtlijnen
- Ingassing /afstemm...
- Processflow
- Beschrijving van de
- Oplijsting proces, d...
- Informatie voor per...
- Consolidatie behoef...
- Openstaande Vrage...

**1 Sommaire**

- Sommaire
- Description du pr
- Conditions annexi
- Lignes de force d...
- Intégration / harm
- Déroulement.....
- Description du dé
- Information sur le
- Consolidation bes
- Questions ouverte

Procesdoc 8 Validation interne et externe

**1 Sommaire**

- Sommaire
- Description du pr
- Conditions annexi
- Lignes de force d...
- Intégration / harm
- Déroulement.....
- Description du dé
- Information sur le
- Consolidation bes
- Questions ouverte

**2 Description du pr**

La définition de la not qualité, de l'exactitude terme de validation. A l qu'un processus déteri préalable" (Huber, 199

Procesdoc 9 Finale validatie en openbaarmaking van de studies

**Inhoud**

- Omschrijving Proce...
- Randvoorwaarden voor het p...
- Ingassing /afstemming met a...
- Processflow
- Beschrijving Flow
- Consolidatie behoeften onder...

**Omschrijving Proce...**

Dit proces omschrijft de beleidsaanbevelingen.

Meer specifiek worden i

- Op basis van ee aan de Raad van

Procesdoc 10 Monitoring van impact

**Inhoud**

- Omschrijving Proce...
- Randvoorwaarden voor het proces...
- Krachtlijnen voor het Proces...
- Ingassing /afstemming met andere processen
- Processflow
- Beschrijving Flow

**Omschrijving Proce...**


Dit proces "monitoring van impact heeft volgende basisdoelstellingen:

- Op periodieke wijze nagaan of beleidsvoorbereidende aanbevelingen van het KCE geleid hebben tot **beleidsbeslissingen**.
- Inhoudelijk wordt nagegaan **in welke mate** de geformuleerde aanbevelingen van het KCE opgevolgd werden.



2003

2006





KCE Reports 174C

STAKEHOLDER INVOLVEMENT IN KCE WORKING PROCESSES



2012 www.kce.fgov.be



KCE Reports 181C

THE USE OF QUALITATIVE RESEARCH METHODS IN KCE STUDIES



2012 www.kce.fgov.be



KCE Reports 183C

BELGIAN GUIDELINES FOR ECONOMIC EVALUATIONS AND BUDGET IMPACT ANALYSES: SECOND EDITION



2012 www.kce.fgov.be

Process Book

Home Bibliography [Restricted access]

Home » KCE Process Book » METHODOLOGICAL APPROACHES » SEARCH FOR EVIDENCE (GCP - HTA) » 3. Searching electronic sources

### 3.1 Sources of biomedical literature

Author(s): Joan Vlayen  
Patrice Chalon

#### Core databases

- MEDLINE contains records from 5600 journals (39 languages) in the of biomedical field, from 1946 onwards (Access for KCE) Free access through PubMed).
- EMBASE: Records from 7600 journals (70 countries, 2000 not covered by Medline) in biomedical field, from 1974 onwards (Access for KCE).
- CENTRAL - The Cochrane Controlled Trials Register, part of the Cochrane Library. Records of randomised controlled trials and controlled clinical trials in healthcare identified through the work of the Cochrane Collaboration including large numbers of records from MEDLINE and EMBASE as well as much material not covered by these databases (Dickinson, 2002). (Access for KCE through CDLH) Free access to abstracts)

#### Databases for systematic reviews


- CRD Database of reviews of effectiveness (DARE) contains structured abstracts, including critical appraisal, of systematic reviews identified by regular searching of bibliographic databases, and handsearching of key journals. [the update of CRD DARE has ceased March 2015]
- Cochrane Database of Systematic Reviews (CDSR, part of the Cochrane Library) lists the results of systematic reviews (full text) conducted by Cochrane groups, but also ongoing projects (Access for KCE through CDLH) Free access to abstracts)
- Special queries exist for Medline or Embase to limit the identified records to articles identified as Systematic reviews. (See appendix).

#### Databases for HTA reports

- The CRD HTA database is a bibliographical database of published HTA reports, it also lists ongoing HTA projects. Members of INAHTA are regularly invited to update their information on the HTA database. Access is free, records of the HTA database are also searchable via the Cochrane Library
- HTA reports can also be found at individual agencies' sites, the HTA vortal lists HTA organisations, it also provides a custom Web search engine that limits the Google results to pages published on the website of HTA organisations listed on the HTA vortal.

Book navigation

- KCE Process Book
- INTRODUCTION
- METHODOLOGICAL APPROACHES
  - SEARCH FOR EVIDENCE (GCP - HTA)
    - 1. Introduction
    - 2. Building a search question
    - 3. Searching electronic sources
      - 3.1 Sources of biomedical literature
      - 3.2 Sources of economic literature
      - 3.3 Sources of clinical practice guidelines
      - 3.4 Sources of ongoing clinical trials
      - 3.5. Sources of grey literature
      - 3.6 Building a search strategy
      - 3.7 Documenting a search strategy
    - 4. Searching supplementary sources
    - 5. Searching for evidence on adverse effects
    - 6. Selecting studies
    - 7. Quality assessment of studies
    - 8. Data extraction
    - 9. Analysing and interpreting results
    - 10. Reporting of the literature review
  - LITERATURE REVIEW AND INTERNATIONAL COMPARISON (HSR)
  - DATA - COLLECTION AND ANALYSIS
  - ECONOMIC EVALUATION AND BUDGET IMPACT ANALYSIS




2004

2006

2012

2017

Other official information and services: [www.fgov.be](http://www.fgov.be) **Overheid**

**Process Book** 

Home Bibliography [Restricted access]

Home » KCE Process Book » METHODOLOGICAL APPROACHES

**LITERATURE REVIEW AND INTERNATIONAL COMPARISON (HSR)**

See the attached document

**Table of content**

1. Introduction
2. Literature review
  1. Introduction
  2. Literature review
  3. Meta review: review of review
3. International comparison
  1. Rationales for international comparisons in HSR research: does an international comparison serve your problem?
  2. Adapt the 'set-up' of the international comparison to the problem you want to address

Attachment	Size
2015-72-(Method)_HSR Process Notes Literature review and international comparison_Report_0.pdf	430.75 KB

1/10 Reporting of the literature review [up](#) [DATA - COLLECTION AND ANALYSIS](#)

Last changed: 23/03/2017

[Printer-friendly version](#) [Login to post comments](#)

**Book navigation**

- ▼ KCE Process Book
  - ▼ INTRODUCTION
  - ▼ METHODOLOGICAL APPROACHES
    - ▼ SEARCH FOR EVIDENCE (GCP - HTA)
    - ▼ LITERATURE REVIEW AND INTERNATIONAL COMPARISON (HSR)
      - ▼ DATA - COLLECTION AND ANALYSIS
      - ▼ ECONOMIC EVALUATION AND BUDGET IMPACT ANALYSIS (HTA)
      - ▼ FORMULATION OF CLINICAL RECOMMENDATIONS (GCP)
      - ▼ GUIDELINE DEVELOPMENT: PRINCIPLES (GCP)
      - ▼ ADAPTE (GCP)
      - ▼ GRADE SYSTEM (GCP, HTA)
      - ▼ RAPID REVIEWS
    - ▼ APPENDICES
    - ▼ COLLOPHON

KCE Report 284Cs



**SYNTHESIS**  
**BETTER TAILORING KCE GUIDELINES TO USERS' NEEDS**



2017

[www.kce.fgov.be](http://www.kce.fgov.be)



KCE PROCESS BOOK  
METHOD



**HSR PROCESS NOTES: LITERATURE REVIEW AND INTERNATIONAL COMPARISON**

PATRIEK MISTAEN, ROOS LEROY, CARINE VAN DE VOORDE, SABINE STORDEUR, KOEN VAN DEN HEEDDE

2016

[www.kce.fgov.be](http://www.kce.fgov.be)

KCE PROCESS NOTES



**METHOD - RAPID REVIEWS**



2017


[www.kce.fgov.be](http://www.kce.fgov.be)



Using KM principles and tools to explore the maintenance process...

# KM EVALUATION

# KM tool 1: SECI Model Knowledge Creation Spiral



# KM tool 2: The KM house model

KM house



Freely inspired by : Knowledge Management in Practice: Connections and Context, Michael Koenig and Taverkere Srikantaiah, Information Today Inc, March 2008  
Transfert des savoirs. Stratégies, moyens d'action, solutions adaptées à votre organisation, Françoise Rossion, Hermès-Lavoisier, Paris, 2008

# Learning from others authors



---

Undertaking Systematic  
Reviews of Research on Effectiveness

---

CRD's Guidance for those Carrying Out  
or Commissioning Reviews

---

*CRD Report Number 4 (2<sup>nd</sup> Edition)*

*March 2001*

 ELSEVIER

Journal of  
Clinical  
Epidemiology

Journal of Clinical Epidemiology 64 (2011) 383–394

**GRADE guidelines: 1. Introduction—GRADE evidence profiles  
and summary of findings tables**

Gordon Guyatt<sup>a,b,c</sup>, Andrew D. Oxman<sup>c</sup>, Elie A. Akl<sup>m</sup>, Regina Kunz<sup>d</sup>, Gunn Vist<sup>e</sup>, Jan Brozek<sup>a</sup>,  
Susan Norris<sup>c</sup>, Yngve Falck-Ytter<sup>f</sup>, Paul Glasziou<sup>g</sup>, Hans deBeer<sup>h</sup>, Roman Jaeschke<sup>b</sup>,  
David Rind<sup>i</sup>, Joerg Meerpohl<sup>l,k</sup>, Philipp Dahm<sup>l</sup>, Holger J. Schünemann<sup>a,b</sup>

<sup>a</sup>Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario L8N 3Z5, Canada  
<sup>b</sup>Department of Medicine, McMaster University, Hamilton, Ontario L8N 3Z5, Canada  
<sup>c</sup>Norwegian Knowledge Centre for the Health Services, St. Olavs plass, 0130 Oslo, Norway  
<sup>d</sup>Academy of Swiss Insurance Medicine, University Hospital Basel, Basel, Switzerland  
<sup>e</sup>Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, OR 97239-3098, USA  
<sup>f</sup>Division of Gastroenterology, Case and VA Medical Center, Case Western Reserve University, Cleveland, OH 44106, USA  
<sup>g</sup>Royal University, Gold Coast, Australia  
<sup>h</sup>Dutch Association of Nursing Home Specialists, Mercatorlaan 1200, 3528 BL Utrecht, The Netherlands  
<sup>i</sup>Harvard Medical School, Uptown, Boston, MA, USA  
<sup>j</sup>German Cochrane Center, Institute of Medical Biometry and Medical Informatics, University Medical Center Freiburg, 79104 Freiburg, Germany  
<sup>k</sup>Department of Pediatric and Adolescent Medicine, Division of Pediatric Hematology and Oncology, University Medical Center Freiburg, 79106 Freiburg, Germany  
<sup>l</sup>Department of Urology, University of Florida, College of Medicine, Gainesville, FL 32610, USA  
<sup>m</sup>Department of Medicine, State University of New York at Buffalo, Buffalo, NY, USA

Accepted 8 April 2010

---

**Abstract**

This article is the first of a series providing guidance for use of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system of rating quality of evidence and grading strength of recommendations in systematic reviews, health technology assessments (HTAs), and clinical practice guidelines addressing alternative management options. The GRADE process begins with asking an explicit question, including specification of all important outcomes. After the evidence is collected and summarized, GRADE provides explicit criteria for rating the quality of evidence that include study design, risk of bias, imprecision, inconsistency, indirectness, and magnitude of effect.

Recommendations are characterized as strong or weak (alternative terms conditional or discretionary) according to the quality of the supporting evidence and the balance between desirable and undesirable consequences of the alternative management options. GRADE suggests summarizing evidence in succinct, transparent, and informative summary of findings tables that show the quality of evidence and the magnitude of relative and absolute effects for each important outcome and/or as evidence profiles that provide, in addition, detailed information about the reason for the quality of evidence rating.

Subsequent articles in this series will address GRADE's approach to formulating questions, assessing quality of evidence, and developing recommendations. © 2011 Elsevier Inc. All rights reserved.

**Keywords:** GRADE; systematic reviews; clinical practice guidelines; health technology assessment; quality of evidence; strength of recommendations

---

**1. Introduction**

The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system has been developed by the GRADE Working Group. The named authors drafted and revised this article. A complete list of contributors to this series can be found on the *Journal of Clinical Epidemiology* website.


\* Corresponding author. CLARTY Research Group, Department of Clinical Epidemiology & Biostatistics, Room 2C12, 1200 Main Street West Hamilton, Ontario L8N 3Z5, Canada. Tel.: +1 905-525-9140; fax: +1 905-524-3841.  
E-mail address: guyatt@mcmaster.ca (G. Guyatt).

0895-4356/\$ - see front matter © 2011 Elsevier Inc. All rights reserved.  
doi:10.1016/j.jclinepi.2010.04.026



# Learning from others

lecturers, trainers, ...



A blue and white banner for the Guidelines International Network event. On the left is the GIN logo. The central text reads "WHY WE DO WHAT WE DO THE PURPOSE AND IMPACT OF GUIDELINES 11 - 14 SEPTEMBER 2018". On the right, it says "LOCAL HOSTS" and lists "NICE National Institute for Health and Care Excellence" and "SIGN". A stylized "M" logo for "G-I-N 2018 MANCHESTER" is also present.

A banner for the HTAi 2017 Annual Meeting. The Roman numeral "XIV" is on the left. The main text reads "HTAi 2017 Annual Meeting Rome, Italy" in yellow and green. Below it is the hashtag "#HTAiRome2017" and the dates "JUNE 17-21, 2017". The background shows a classical building facade.

A banner for the Global Evidence Summit. It features a collage of images: a landscape with mountains, a family, a person with arms raised, and flags. The central logo is a colorful triangle with the text "Global Evidence Summit Using evidence. Improving lives. 12-16 Sept 17 | Cape Town, South Africa".

# Learning from others

co-authors, validators, stakeholders, ...



KCE REPORT 271  
HEALTH SERVICES RESEARCH  
Project run in close collaboration with Zorginstituut Nederland



## FUTURE SCENARIOS ABOUT DRUG DEVELOPMENT AND DRUG PRICING

PHILIPPE VANDENBROECK, PETER RAEYMAKERS, RACHEL WICKERT, KIM BECHER, JO GOOSSSENS, IRINA CLEEMPUT, FRANK HULSTAERT, LYDIA DE HEIJ, RAF MERTENS

2016

[www.kce.fgov.be](http://www.kce.fgov.be)



### COLOPHON

Title:	Management of pancreatic cancer: capita selecta – Part 1: Introduction and methodology
Authors:	Geneviève Veereman (KCE), Nadia Haj Mohammad (Dutch Cochrane Centre), Maarten Van Leeuwen (Dutch Cochrane Centre), Rob Scholten (Dutch Cochrane Centre), Hans Van Brabant (KCE)
Guideline Development Group:	Marc Peeters (President of the GDG, UZA), Frederik Berrevoet (UGent), Ivan Borbath (Cliniques universitaires Saint-Luc), Donald Claeys (AZMMSJ), Joelle Collignon (UZ Leuven), Pieter Demetter (Hôpital Erasme), Karen Geboes (UGent), Karin Hausermans (UZ Leuven), Mina Komuta (Cliniques universitaires Saint-Luc), Philippe Malvaux (CHWAPI, Tournai), Els Monsaert (AZMMSJ), Hans Prenen (CHU Liège), Geert Roeyen (UZA), Bart Smet (AZ Delta), Sigrid Stroobants (UZA), Baki Topal (UZ Leuven), Eric Van Cutsem (UZ Leuven), Daniel Van Daele (CHU Liège), Daniel Van Gansbeke (Hôpital Erasme), Jean-Luc Van Laethem (Hôpital Erasme), Joseph Weerts (CHC Liège)
Scoping of the guideline:	Frederik Berrevoet (UGent), Alain Bols (BSMO), Nicolas Christian (BVRO – ABRO), An Claes (Kom op tegen Kanker), Wim Demey (BSMO), Joelle Collignon (UZ Leuven), Pieter Demetter (Hôpital Erasme), Lorraine Donnay (BVRO-ABRO), Karen Geboes (UGent), Bernard Geurde (BGES), Anne Hoorens (BVP-SBP), Catherine Hubert (BSHBPS – RBSS), Philippe Malvaux (CHWAPI, Tournai), Els Monsaert (AZMMSJ), Geert Roeyen (UZA), Raphael Rubay (BGES), Marc Simoens (VVGGE), Bart Smet (AZ Delta), Baki Topal (UZ Leuven), Daniel Van Daele (CHU Liège), Nancy Van Damme (Stichting Kanker Register), Daniel Van Gansbeke (Hôpital Erasme), Jean-Luc Van Laethem (Hôpital Erasme), Joseph Weerts (CHC Liège), Dirk Ysebaert (BSSO)
Project Coordinator:	Sabine Stordeur (KCE)
Reviewers:	Anja Desomer (KCE), Raf Mertens (KCE), Joan Viayen (KCE)
Stakeholders:	Alain Bols (BSMO), Nicolas Christian (BVRO – ABRO), An Claes (Kom op tegen Kanker), Wim Demey (BSMO), Lorraine Donnay (BVRO – ABRO), Bernard Geurde (BGES), Anne Hoorens (BVP – SBP), Catherine Hubert (BSHBPS – RBSS), Raphael Rubay (BGES), Marc Simoens (VVGGE), Nancy Van Damme (Stichting KankerRegister), Didier Van der Steichel (Fondation Contre le Cancer), Dirk Ysebaert (BSSO)
External validators:	Marco Bruno (University Medical Center Rotterdam), Bas Groot Koerkamp (University Medical Center Rotterdam), Thomas Seufferlein (Universitätsklinikum Ulm)
Other reported interests:	Membership of a stakeholder group on which the results of this report could have an impact: Alain Bols (BSMO), Marco Bruno (ESDO), Wim Demey (BSMO), Els Monsaert (VVGGE), Marc Simoens (VVGGE), Didier Van der Steichel (General Director, Fondation contre le Cancer) Participation in scientific or experimental research as an initiator, principal investigator or researcher: Marco Bruno (multiple studies), Karen Geboes (many commercial studies related to metastatic pancreatic cancer), Karin

# Learning from experience







Figure used in KCE report 156C "Home oxygen therapy", page 11<sup>1</sup>. Source: Hulpmiddelen Kompas 2004, Zuurstofapparatuur – ISBN 90-70918-38-2



# Identifying opportunities



## Mixed Treatment Comparison (MTC) – Network Meta-analysis

29/09/2014

France Vrijens

.be

Include in our processes?



- Accepted by NICE
- To be discussed – decision case per case
- A method TPF will be introduced for the 2015 work program

42

www.kce.fgov.be 






# CONCLUSION



# Maintenance of KCE methods guides fulfil the KM models




# Moving out of the “Office” format is a challenge

**KCE**  
Federaal Kenniscentrum voor de Gezondheidszorg  
Centre Fédéral d'Évaluation des Soins de Santé  
Belgian Health Care Knowledge Centre

**KCE Report 183C**

**BELGIAN GUIDELINES FOR ECONOMIC EVALUATIONS AND BUDGET IMPACT ANALYSES: SECOND EDITION**





**2012**    **KCE PROCESS BOOK**  
METHOD

**KCE**  
Federaal Kenniscentrum voor de Gezondheidszorg  
Centre Fédéral d'Évaluation des Soins de Santé  
Belgian Health Care Knowledge Centre

**HSR PROCESS NOTES: LITERATURE REVIEW AND INTERNATIONAL COMPARISON**

**PATRIEK MIBTS**  
**2011**    **KCE PROCESS NOTES**

**METHOD – RAPID REVIEWS**



**2011**    [www.kce.fgov.be](http://www.kce.fgov.be)  
**be**





# There are always more topics to consider

- Patient's involvement



- ....





Image source: <https://images-eu.ssl-images-amazon.com/images/I/51RG5V4YPJL.jpg>

# Research projects are continuously adjusted



## PRIORITIES

- 1.
- 2.
- 3.
- ...

# Option for a manageable future...




Image source: [http://2.bp.blogspot.com/-otdh9S613J8/Tam\\_YAWNk9I/AAAAAAAAAkc/6ON8bk4KPIE/s1600/douglasfairbanks.jpg](http://2.bp.blogspot.com/-otdh9S613J8/Tam_YAWNk9I/AAAAAAAAAkc/6ON8bk4KPIE/s1600/douglasfairbanks.jpg)



Federaal Kenniscentrum voor de Gezondheidszorg  
Centre Fédéral d'Expertise des Soins de Santé  
Belgian Health Care Knowledge Centre



<http://processbook.kce.fgov.be>



<http://www.kce.fgov.be>



<http://twitter.kce.fgov.be>



<http://linkedin.kce.fgov.be>



<http://youtube.kce.fgov.be>



<http://facebook.kce.fgov.be>

*Follow us!*

